ReviewFrontiers in immunology2022
Implications of the Immune Landscape in COPD and Lung Cancer: Smoking Versus Other Causes.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07543601 (Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention), which is not on this map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhanced COPD Management in Suspected Lung Cancer Patients - Improving Outcomes Through Timely Intervention
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Efficacy and safety of CT-guided 125I particle implantation for the treatment of elderly lung cancer: a system evaluation and meta-analysis.BMC geriatrics · 2025Pooled it
- The impact of chronic obstructive pulmonary disease on the risk of immune-related pneumonitis in lung cancer patients undergoing immunotherapy: a systematic review and meta-analysis.BMC pulmonary medicine · 2024Pooled it
- Review of quantitative and functional lung imaging evidence of vaping-related lung injury.Frontiers in medicine · 2024Pooled it
- ADHD-anchored partitioning of non-small cell lung cancer genetic covariance identifiesFrontiers in immunology · 2026Article
- Unravelling the role of nanomedicine in attenuating inflammation, oxidative stress and cellular ageing in chronic obstructive pulmonary disease.Archives of toxicology · 2025Review
- Beyond Smoking: Emerging Drivers of COPD and Their Clinical Implications in Low- and Middle-Income Countries: A Narrative Review.Journal of clinical medicine · 2025Review
- DC-SIGN (CD209)-mediated interactions between bacteria, lung cancer tissues, and macrophages promote cancer metastasis.Infectious agents and cancer · 2025Article
- The Multifaceted Roles of Neutrophil Death in COPD and Lung Cancer.Journal of respiratory biology and translational medicine · 2025Article
- Review
- Exploring the Diagnostic and Prognostic Predictive Values of Ferroptosis-related Markers in Lung Adenocarcinoma.Current pharmaceutical biotechnology · 2025Article
- The causal and mediation effect of chronic obstructive pulmonary disease on lung cancer subtypes: a two-sample mendelian randomization study.Cancer causes & control : CCC · 2025Article
- Chronic obstructive pulmonary disease burden attributable to tobacco and the trend change from 1990 to 2021 in China.Tobacco induced diseases · 2025Article
- Artemisinin and its derivatives: all-rounders that may prevent the progression from lung injury to lung cancer.Frontiers in pharmacology · 2025Review
- Inhalation of patchouli essential oil alleviates airway inflammation in cigarette smoke-induced COPD mice.Scientific reports · 2024Article
- Third-Hand Smoke Exacerbates HTurkish journal of pharmaceutical sciences · 2024Article
- Does Tobacco Smoking Affect Vaccine-Induced Immune Response? A Systematic Review and Meta-Analysis.Vaccines · 2024Review
- IL-22: A key inflammatory mediator as a biomarker and potential therapeutic target for lung cancer.Heliyon · 2024Review
- MicroRNA mediated suppression of airway lactoperoxidase by TGF-β1 and cigarette smoke promotes airway inflammation.Journal of inflammation (London, England) · 2024Article
- A review on current advancement in zebrafish models to study chronic inflammatory diseases and their therapeutic targets.Heliyon · 2024Review
- Prognostic value of tumor‑associated CD177Oncology letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cigarette smoking is reported in about one third of adults worldwide. A strong relationship between cigarette smoke exposure and chronic obstructive pulmonary disease (COPD) as well as lung cancer has been proven. However, about 15% of lung cancer cases, and between one fourth and one third of COPD cases, occur in never-smokers. The effects of cigarette smoke on the innate as well as the adaptive immune system have been widely investigated. It is assumed that certain immunologic features contribute to lung cancer and COPD development in the absence of smoking as the major risk factor. In this article, we review different immunological aspects of lung cancer and COPD with a special focus on non-smoking related risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.